阿托伐他汀治疗多囊卵巢综合征与患者25-羟维生素D水平的关系

发布时间：2018-11-11 13:54

【摘要】：目的探讨阿托伐他汀治疗多囊卵巢综合征(PCOS)时,患者血清25-羟维生素D(25-OHD)水平与睾酮、稳态模型胰岛素抵抗(HOMA-IR)指数及超敏C反应蛋白(hs CRP)相关性。方法选择PCOS患者50例,随机分为2组,每组各25例。对照组给予安慰剂治疗;实验组给予阿托伐他汀治疗;治疗周期均为3个月。测定治疗前后25-OHD、睾酮、HOMA-IR及hs CRP,并分析25-OHD与睾酮、HOMA-IR和hs-CRP的相关性。结果实验组治疗后与治疗前比较,25-OHD升高,睾酮、HOMA-IR及hs-CRP均降低(P0.05),治疗后25-OHD与hs CRP呈负相关(P0.05);对照组治疗前后25-OHD、睾酮、HOMA-IR及hs-CRP差异无统计学意义(P0.05)。结论阿托伐他汀可改善PCOS患者的胰岛素抵抗(IR)和高雄血症,对预防其发生远期心血管疾病有益,可能与25-OHD升高有关。
[Abstract]:Objective to investigate the correlation between serum 25-hydroxyvitamin D (25-OHD) and testosterone, insulin resistance (HOMA-IR) index of steady-state model and high sensitive C-reactive protein (hs CRP) in patients with polycystic ovary syndrome (PCOS) treated with Atto vastatin. Methods 50 patients with PCOS were randomly divided into two groups, 25 cases in each group. The control group was given placebo and the experimental group was treated with Atto vastatin for 3 months. The levels of 25-OHD, testosterone, HOMA-IR and hs CRP, were measured before and after treatment and the correlation between 25-OHD and testosterone, HOMA-IR and hs-CRP was analyzed. Results compared with before treatment, 25-OHD increased, testosterone, HOMA-IR and hs-CRP decreased in experimental group (P0.05), and 25-OHD and hs CRP were negatively correlated after treatment (P0.05). There was no significant difference in 25-OHD, testosterone, HOMA-IR and hs-CRP before and after treatment in the control group (P0.05). Conclusion Atto vastatin can improve insulin resistance (IR) and hyperandrogenemia in patients with PCOS. It is beneficial to prevent long-term cardiovascular disease and may be related to the increase of 25-OHD.
【作者单位】：河北医科大学第四医院;河北省胸科医院;
【基金】：河北省医学科学研究课题计划(No:20130239)
【分类号】：R711.75

【共引文献】